Review Article
Volume: 40 | Issue: 3 | Published: Sep 25, 2024 | Pages: 119 - 122 | DOI: 10.24911/BioMedica/5-1181
Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets
Authors: Mohammad Ali , Urbah Viqar
Article Info
Authors
Mohammad Ali
Dr Akbar Niazi Teaching Hospital, Bharakhu, Main Murree Road, Islamabad, Pakistan
Urbah Viqar
Clinical Fellow Psychiatry, Addiction Recovery Community Hillingdon (ARCH), London, UK
Publication History
Received: July 03, 2024
Revised: August 18, 2024
Accepted: September 13, 2024
Published: September 25, 2024
Abstract
Psychiatric disorders are some of the major challenges facing treatment in as much as response rates and recoveries are concerned because these mental disorders are acknowledged for their devastating effects. Another area explored in this research looks into the functioning of liberal motives in the glutamatergic system, immunologic system, and neuroinflammation as specifications that could be utilized for managing psychiatric disorders with the help of medications. Two main strategies are; regulation of the release of glutamate and immune reactions, and neuroinflammation. The efficacy of such systems has been demonstrated from preclinical and clinical trials, mainly in the enhancement of mental symptoms. Though, questions arise like: Is it feasible to develop the target? Do the emitting pole and the receiving pole indicate that the treatment is the best one? On what basis should the patients be grouped? Assessing such priceless information concerning these novel targets will enable the identification of the course towards the personal and appropriate medication for patients with psychiatric ailments. The discoveries in this article will shed light on the new potential therapeutic targets for the psychiatric diseases, which will point towards the potential new directions for the treatment for the mental health disorders that may revolutionise the treatment outcomes for the psychiatric patients and force the changes in the mental healthcare system.
Keywords: psychiatric illnesses, neuroinflammation, glutamatergic neurotransmission, glutamatergic system
Pubmed Style
Mohammad Ali, Urbah Viqar. Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets. BioMedica. 2024; 25 (September 2024): 119-122. doi:10.24911/BioMedica/5-1181
Web Style
Mohammad Ali, Urbah Viqar. Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets. https://biomedicapk.com/articles/1181 [Access: March 25, 2025]. doi:10.24911/BioMedica/5-1181
AMA (American Medical Association) Style
Mohammad Ali, Urbah Viqar. Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets. BioMedica. 2024; 25 (September 2024): 119-122. doi:10.24911/BioMedica/5-1181
Vancouver/ICMJE Style
Mohammad Ali, Urbah Viqar. Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets. BioMedica. (2024), [cited March 25, 2025]; 25 (September 2024): 119-122. doi:10.24911/BioMedica/5-1181
Harvard Style
Mohammad Ali, Urbah Viqar (2024) Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets. BioMedica, 25 (September 2024): 119-122. doi:10.24911/BioMedica/5-1181
Chicago Style
Mohammad Ali, Urbah Viqar. "Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets." 25 (2024), 119-122. doi:10.24911/BioMedica/5-1181
MLA (The Modern Language Association) Style
Mohammad Ali, Urbah Viqar. "Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets." 25.September 2024 (2024), 119-122. Print. doi:10.24911/BioMedica/5-1181
APA (American Psychological Association) Style
Mohammad Ali, Urbah Viqar (2024) Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets. , 25 (September 2024), 119-122. doi:10.24911/BioMedica/5-1181